BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29477101)

  • 1. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
    Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
    Olsen E; Vonderheid E; Pimpinelli N; Willemze R; Kim Y; Knobler R; Zackheim H; Duvic M; Estrach T; Lamberg S; Wood G; Dummer R; Ranki A; Burg G; Heald P; Pittelkow M; Bernengo MG; Sterry W; Laroche L; Trautinger F; Whittaker S;
    Blood; 2007 Sep; 110(6):1713-22. PubMed ID: 17540844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
    J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
    Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
    Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
    Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
    Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4
    Vonderheid EC; Hou JS
    Leuk Lymphoma; 2018 Feb; 59(2):330-339. PubMed ID: 28595473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.
    Gibson JF; Huang J; Liu KJ; Carlson KR; Foss F; Choi J; Edelson R; Hussong JW; Mohl R; Hill S; Girardi M
    J Am Acad Dermatol; 2016 May; 74(5):870-7. PubMed ID: 26874819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
    Thomas BR; Whittaker S
    Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
    Kim YH; Willemze R; Pimpinelli N; Whittaker S; Olsen EA; Ranki A; Dummer R; Hoppe RT;
    Blood; 2007 Jul; 110(2):479-84. PubMed ID: 17339420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
    Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
    Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
    Olsen EA
    Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.